BACKGROUND: Fatty liver is commonly associated with insulin-resistant conditions, often related to increased abdominal visceral fat. Our objective was to elucidate the specific roles of obesity, type 2 diabetes mellitus, insulin-resistance and abdominal fat distribution. MATERIALS AND METHODS: The study population comprised 13 diabetic obese (DO), 10 nondiabetic obese (NDO), and nine normal-weight control (C) men aged 28-65 years, with normal plasma triglyceride levels. DO were in good glycaemic control (HbA1c = 6·8 ± 0·8%) (M ± SD) with diet (n = 8) or diet + metformin (n = 5). Liver fat content was measured by (1) H-magnetic resonance spectroscopy, abdominal fat distribution by magnetic resonance imaging and insulin sensitivity by hyperinsulinaemic euglycaemic clamp. RESULTS: DO and NDO subjects had similar whole-body insulin resistance, BMI and waist circumference, higher than those of C subjects (P < 0·001). DO had more liver fat (11·9 ± 7·0%) than NDO (5·2 ± 2·8%, P < 0·05) and C (1·6 ± 1·0%, P < 0·001). Abdominal fat was greater in DO and NDO than in C (visceral: DO 3184 ± 843, NDO 2843 ± 1378 vs. C 1212 ± 587 cm(3), P < 0·001; subcutaneous: DO 4029 ± 362, NDO 5197 ± 1398 vs. C 2312 ± 626 cm(3), P < 0·001), visceral fat being not significantly different between the two obese groups, and subcutaneous fat significantly less in DO than in NDO (P < 0·05). CONCLUSIONS: Type 2 diabetes is associated with increased fat accumulation in the liver, independent of obesity and whole-body insulin resistance. The increased liver fat in DO patients may be part of an altered regional fat distribution that includes an inadequate subcutaneous fat storing capacity, rather than simply being a consequence of increased abdominal visceral content.
BACKGROUND: Fatty liver is commonly associated with insulin-resistant conditions, often related to increased abdominal visceral fat. Our objective was to elucidate the specific roles of obesity, type 2 diabetes mellitus, insulin-resistance and abdominal fat distribution. MATERIALS AND METHODS: The study population comprised 13 diabetic obese (DO), 10 nondiabetic obese (NDO), and nine normal-weight control (C) men aged 28-65 years, with normal plasma triglyceride levels. DO were in good glycaemic control (HbA1c = 6·8 ± 0·8%) (M ± SD) with diet (n = 8) or diet + metformin (n = 5). Liver fat content was measured by (1) H-magnetic resonance spectroscopy, abdominal fat distribution by magnetic resonance imaging and insulin sensitivity by hyperinsulinaemic euglycaemic clamp. RESULTS: DO and NDO subjects had similar whole-body insulin resistance, BMI and waist circumference, higher than those of C subjects (P < 0·001). DO had more liver fat (11·9 ± 7·0%) than NDO (5·2 ± 2·8%, P < 0·05) and C (1·6 ± 1·0%, P < 0·001). Abdominal fat was greater in DO and NDO than in C (visceral: DO 3184 ± 843, NDO 2843 ± 1378 vs. C 1212 ± 587 cm(3), P < 0·001; subcutaneous: DO 4029 ± 362, NDO 5197 ± 1398 vs. C 2312 ± 626 cm(3), P < 0·001), visceral fat being not significantly different between the two obese groups, and subcutaneous fat significantly less in DO than in NDO (P < 0·05). CONCLUSIONS: Type 2 diabetes is associated with increased fat accumulation in the liver, independent of obesity and whole-body insulin resistance. The increased liver fat in DO patients may be part of an altered regional fat distribution that includes an inadequate subcutaneous fat storing capacity, rather than simply being a consequence of increased abdominal visceral content.
Authors: Manoj Kumar Sarma; Andres Saucedo; Christine Hema Darwin; Ely Richard Felker; Kavya Umachandran; Daniel Kohanghadosh; Edward Xu; Steve Raman; Michael Albert Thomas Journal: Magn Reson Imaging Date: 2020-07-12 Impact factor: 2.546
Authors: Lance E Davidson; David E Kelley; Stanley Heshka; John Thornton; F Xavier Pi-Sunyer; Lawrence Boxt; Ashok Balasubramanyam; Dympna Gallagher Journal: J Appl Physiol (1985) Date: 2014-06-19
Authors: Subhash Kamath; Alberto O Chavez; Amalia Gastaldelli; Francesca Casiraghi; Glenn A Halff; Gregory A Abrahamian; Alberto M Davalli; Raul A Bastarrachea; Anthony G Comuzzie; Rodolfo Guardado-Mendoza; Lilia M Jimenez-Ceja; Vicki Mattern; Ana Maria Paez; Andrea Ricotti; Mary E Tejero; Paul B Higgins; Iram Pablo Rodriguez-Sanchez; Devjit Tripathy; Ralph A DeFronzo; Edward J Dick; Gary W Cline; Franco Folli Journal: PLoS One Date: 2011-11-18 Impact factor: 3.240
Authors: Lutgarda Bozzetto; Anna Prinster; Giovanni Annuzzi; Lucia Costagliola; Anna Mangione; Alessandra Vitelli; Raffaella Mazzarella; Margaret Longobardo; Marcello Mancini; Carlo Vigorito; Gabriele Riccardi; Angela A Rivellese Journal: Diabetes Care Date: 2012-07 Impact factor: 19.112
Authors: Charlyn G Partridge; Gloria L Fawcett; Bing Wang; Clay F Semenkovich; James M Cheverud Journal: BMC Genomics Date: 2014-02-05 Impact factor: 3.969